Cargando…

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera available at start of therapy, during therapy and at disease progression were selected from 10 estrogen receptor (ER)-positive breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Maurice P.H.M., Martens, John W.M., Helmijr, Jean C.A., Beaufort, Corine M., van Marion, Ronald, Krol, Niels M.G., Monkhorst, Kim, Trapman-Jansen, Anita M.A.C., Meijer-van Gelder, Marion E., Weerts, Marjolein J.A., Ramirez-Ardila, Diana E., Jan Dubbink, Hendrikus, Foekens, John A., Sleijfer, Stefan, Berns, Els M.J.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190033/ https://www.ncbi.nlm.nih.gov/pubmed/27270325 http://dx.doi.org/10.18632/oncotarget.9727

Ejemplares similares

Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA
por: Weerts, Marjolein J. A., et al.
Publicado: (2017)

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis
por: Ramirez-Ardila, Diana, et al.
Publicado: (2017)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
por: de Kruijff, Ingeborg E., et al.
Publicado: (2018)

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
por: Jansen, M. P. H. M., et al.
Publicado: (2011)

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer
por: Klijn, JGM, et al.
Publicado: (2005)

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
por: Umar, Arzu, et al.
Publicado: (2009)

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers
por: Weerts, Marjolein J. A., et al.
Publicado: (2018)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
por: Jongbloed, Elisabeth M., et al.
Publicado: (2023)

Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions
por: van Dessel, Lisanne F., et al.
Publicado: (2017)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010)

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA()()
por: Weerts, M.J.A., et al.
Publicado: (2018)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

Compartmentalization of androgen receptor protein–protein interactions in living cells
por: van Royen, Martin E., et al.
Publicado: (2007)

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
por: Beaufort, Corine M., et al.
Publicado: (2014)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
por: Bos, Manouk K., et al.
Publicado: (2020)

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
por: Ge, Zhouhong, et al.
Publicado: (2021)

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
por: Schrohl, Anne-Sofie, et al.
Publicado: (2009)

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
por: Luo, L-Y, et al.
Publicado: (2002)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017)

Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease
por: Foekens, J A, et al.
Publicado: (2003)

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
por: van Agthoven, T, et al.
Publicado: (2009)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer
por: Liu, Jingjing, et al.
Publicado: (2016)

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds
por: Mustafa, Dana A. M., et al.
Publicado: (2015)

High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
por: van Dessel, Lisanne F., et al.
Publicado: (2018)

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Loss of Y-Chromosome during Male Breast Carcinogenesis
por: Agahozo, Marie Colombe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qin5r1h4iep1fo4mha31m73hip